Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (92 total)
-
Creator: Muster, Viktoria, Thomas Gary, Reinhard B. Raggam, Albert WÖlfler, and Marianne Brodmann.
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-04-14
Description: Clinical Picture of a Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination in a 51-year-old woman -
Creator: Greinacher, Andreas, Thomas Thiele, Theodore E. Warkentin, Karin Weisser, Paul A. Kyrle, and Sabine Eichinger.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-09
Description: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1… -
Creator: Schultz, Nina H., Ingvild H. Sørvoll, Annika E. Michelsen, Ludvig A. Munthe, Fridtjof Lund-Johansen, Maria T. Ahlen, Markus Wiedmann, Anne-Hege Aamodt, Thor H. Skattør, Geir E. Tjønnfjord, and Pål A. Holme.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-09
Description: We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). -
Creator: the mRNA-1273 Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-06
Description: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19). -
Creator: the Oxford COVID-19 Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-30
Description: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. -
Creator: Keehner, Jocelyn, Lucy E. Horton, Michael A. Pfeffer, Christopher A. Longhurst, Robert T. Schooley, Judith S. Currier, Shira R. Abeles, and Francesca J. Torriani.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-23
Description: Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose…Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Creator: Benenson, Shmuel, Yonatan Oster, Matan J. Cohen, and Ran Nir-Paz.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-23
Description: The surge of coronavirus disease 2019 (Covid-19) around the world and the need for urgent and intensive medical care have weighed heavily on health care systems and hospitals.Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Creator: CDC
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-01-08
Description: This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States. The vaccine contains rice-derived recombinant human serum albumin and… -
Creator: Ella, Raches, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-08
Description: BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-blind, multicentre, randomised, controlled… -
Creator: Liu, Yang, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R.…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-08
Description: BNT162b2 is a nucleoside-modified RNA vaccine expressing the full-length prefusion spike glycoprotein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a randomized, placebo-controlled clinical trial involving approximately…